Overture Life Secures EIB Support to Boost Automation and Accessibility in Reproductive Healthcare

Overture Life Secures EIB Support to Boost Automation and Accessibility in Reproductive Healthcare

(IN BRIEF) The European Investment Bank (EIB) has provided a €20 million loan to Overture Life to develop automated and AI-driven technologies for in vitro fertilization (IVF) and egg freezing. The funding supports the company’s R&D, production expansion, and clinical trials, enabling wider access to fertility care and improved pregnancy outcomes. Signed at Bio-Europe 2025, the agreement contributes to the EIB’s TechEU and InvestEU initiatives, which aim to strengthen Europe’s innovation ecosystem and healthcare resilience.

(PRESS RELEASE) LUXEMBOURG, 4-Nov-2025 — /EuropaWire/ — The European Investment Bank (EIB) has signed a €20 million financing agreement with Overture Life SLU, a Spanish biotech company pioneering the automation of in vitro fertilization (IVF) and egg-freezing technologies. The loan will support the company’s research, development, and commercialisation of AI-powered reproductive health innovations designed to make IVF more effective, affordable, and accessible for women worldwide.

Signed during the Women Leaders in Life Science conference organised by the EIB Group at Bio-Europe in Vienna, the agreement underscores the EU’s commitment to fostering healthcare innovation and promoting women’s reproductive health. The investment forms part of the TechEU initiative, the EIB Group’s flagship programme to accelerate innovation across Europe, backed by the InvestEU programme.

With birth rates declining globally and access to assisted reproductive technologies limited in many regions, Overture Life is using automation and AI to improve the IVF process from start to finish. Its DaVitri vitrification platform—a compact, fully automated tabletop device—streamlines the egg-freezing process by standardising complex manual steps, minimising user error, and reducing dependency on specialised embryologists. The system’s design allows it to integrate easily into both new and existing IVF laboratories, making fertility preservation more widely available and efficient.

The funding will also support the company’s development of non-invasive, AI-driven tools that analyse embryo metabolomics to predict implantation success rates. These technologies aim to enhance clinical outcomes while addressing cost and accessibility barriers in reproductive care.

“We are delighted to collaborate with innovative biotech companies like Overture Life, whose work directly improves people’s lives,” said Karl Nehammer, EIB Vice-President. “This investment reinforces our mission to support technological progress in Europe and highlights how digitalisation and AI can drive groundbreaking advancements in healthcare.”

Hans Gangeskar, CEO of Overture Life, added: “This partnership with the EIB represents far more than a financial boost. It signals a shared recognition of how urgent and transformative reproductive innovation can be. Europe is showing leadership by investing in the technologies that can expand fertility access and freedom for future generations.”

The EIB’s support aligns with its 2024–2027 Strategic Roadmap, which prioritises digital transformation, innovation, and healthcare advancement. Through TechEU, the EIB Group aims to mobilise €250 billion in innovation investments by 2027, while InvestEU—the EU’s flagship funding programme—seeks to unlock €372 billion in additional public and private capital to advance key policy goals across member states.

By supporting Overture Life’s groundbreaking work, the EIB continues to position Europe at the forefront of medical innovation, ensuring that the next generation of reproductive technologies can deliver greater equality, accessibility, and success in fertility care.

Background information

EIB

The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States. Built around eight core priorities, it finances investments that pursue EU policy objectives by bolstering climate action and the environment, digitalisation and technological innovation, security and defence, cohesion, agriculture and bioeconomy, social infrastructure, the capital markets union, and a stronger Europe in a more peaceful and prosperous world.

The EIB Group, which also includes the European Investment Fund (EIF), signed nearly €89 billion in new financing for over 900 high-impact projects in 2024, boosting Europe’s competitiveness and security.

Around half of EIB financing in the European Union goes to cohesion regions, where per capita income is below the EU average, while almost 60% of annual EIB Group investments support climate action and environmental sustainability.

In Spain, the EIB Group signed new financing worth €12.3 billion for over 100 high-impact projects in 2024, contributing to the country’s green and digital transition, economic growth, competitiveness and better services for its people.

High-quality, up-to-date photos of EIB headquarters for media use are available here.

InvestEU

The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilise private investments for the European Union’s policy priorities, such as the European Green Deal and the digital transition. The InvestEU programme brings together under one roof the multitude of EU financial instruments currently available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is implemented through financial partners that will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.”

Overture Life

Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly egg freezing and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company’s DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture’s backers include Overwater Ventures, GV, Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.

Building on a recent venture capital-backed financing round in the U.S., Overture Life has now raised about $70 million to support its trailblazing efforts to use automation and AI to address IVF bottlenecks. Following local regulatory clearances, its DaVitri device launched earlier this year in multiple countries across South and Central America, most recently in Brazil. DaVitri is also in clinical testing in the U.S., where supply bottlenecks have driven the cost of a single IVF cycle to $15,000 or more.

The rest of Overture Life’s innovative portfolio continues to mature as well. Use of its ICSI.A robot resulted in the first two live births resulting from an automated fertilization device in 2023, and its AI+metabolomics-based m|z platform for non-invasive healthy embryo selection is now accessible through a CLIA (Clinical Laboratory Improvement Amendments)-certified laboratory in Texas.

Media contact:
Maite Cordero
m.corderomunoz@eib.org
+34 606 66 82 62

Press Office
press@eib.org
+352 43791

SOURCE: European Investment Bank